A research team from Dana-Farber/Boston Children's Cancer and Blood Disorders Center and other institutions has discovered a new genetic target for potential therapy of sickle cell disease (SCD). The target, called an enhancer, controls a molecular switch in red blood cells called BCL11A that, in turn, regulates hemoglobin production.
The researchers—led by Daniel Bauer, MD, PhD, and Stuart Orkin, MD, of Dana-Farber/Boston Children's—reported their findings today in Science.
Prior work by Orkin and others has shown that when flipped off, BCL11A causes red blood cells to produce fetal hemoglobin that, in SCD patients, is unaffected by the sickle cell mutation and counteracts the deleterious effects of sickle hemoglobin. BCL11A is thus an attractive target for treating SCD.
The disease affects roughly 90,000 to 100,000 people in the United States and millions worldwide.
However, BCL11A plays important roles in other cell types, including the immune system's antibody-producing B cells, which raises concerns that targeting it directly in sickle cell patients could have unwanted consequences.
The discovery of this enhancer—which regulates BCL11A only in red blood cells—opens the door to targeting BCL11A in a more precise manner. Approaches that disable the enhancer would have the same end result of turning on fetal hemoglobin in red blood cells due to loss of BCL11A, but without off-target effects in other cell types.
The findings were spurred by the observation that some patients with SCD spontaneously produce higher levels of fetal hemoglobin and enjoy an improved prognosis. The researchers found that these individuals possess naturally occurring beneficial mutations that function to weaken the enhancer, turning BCL11A's activity down and allowing red blood cells to manufacture some fetal hemoglobin.
"This finding gives us a very specific target for sickle cell disease therapies," said Orkin, a leader of Dana-Farber/Boston Children's who serves as chairman of pediatric oncology at Dana-Farber Cancer Institute and associate chief of hematology/oncology at Boston Children's Hospital. "Coupled with recent advances in technologies for gene engineering in intact cells, it could lead to powerful ways of manipulating hemoglobin production and new treatment options for hemoglobin diseases."
"This is a very exciting study," said Feng Zhang, PhD, a molecular biologist and specialist in genome engineering at the McGovern Institute for Brain Research at the Massachusetts Institute of Technology (MIT) and the Broad Institute of MIT and Harvard, who was not involved in the study. "The findings suggest a potential new approach to treating sickle cell disease and related diseases, one that relies on nucleases to remove this regulatory region, rather than adding an exogenous gene as in classic gene therapy."
Explore further: Researchers highlight potential gene therapy approach to sickle cell disease
More information: "An Erythroid Enhancer of BCL11A Subject to Genetic Variation Determines Fetal Hemoglobin Level" Science, 2013.
Medical Xpress on facebook
Related Stories
Researchers highlight potential gene therapy approach to sickle cell disease
Dec 11, 2012
Researchers at Dana-Farber/Children's Hospital Cancer Center (DF/CHCC) have taken the first preliminary steps toward developing a form of gene therapy for sickle cell disease. In an abstract presented on Dec. 10 at the 54th ...
Scientists reverse sickle cell anemia by turning on fetal hemoglobin
Oct 13, 2011
Not long after birth, human babies transition from producing blood containing oxygen-rich fetal hemoglobin to blood bearing the adult hemoglobin protein. For children with sickle cell disease, the transition from the fetal ...
New approach to sickle-cell disease shows promise in mice
Dec 07, 2009
A new genetic approach to treating sickle cell disease is showing promising results in mice, report researchers from Children's Hospital Boston. By inactivating a gene they previously discovered to be important in the laboratory, ...
Researchers find new genetic target for sickle cell disease therapy
Dec 04, 2008
Researchers have identified a gene that directly affects the production of a form of hemoglobin that is instrumental in modifying the severity of the inherited blood disorders sickle cell disease and thalassemia. The discovery ...
Gene variant linked to moderated symptoms of beta-thalassemia
Jan 30, 2008
Beta-thalassemia is a serious, potentially life-threatening disease that affects red blood cells, cells that carry oxygen via hemoglobin throughout the body. As part of the SardiNIA Study of Aging, supported by the National ...
Recommended for you
Molecule produced during exercise boosts brain health
1 hour ago
Research has shown that exercise is good for the brain. Now investigators have identified a molecule called irisin that is produced in the brain during endurance exercise and has neuroprotective effects. Researchers were ...
Circadian rhythms in skin stem cells protect us against UV rays
2 hours ago
Human skin must cope with UV radiation from the sun and other harmful environmental factors that fluctuate in a circadian manner. A study published by Cell Press on October 10th in the journal Cell Stem Cell has revealed that h ...
How a ubiquitous herpesvirus sometimes leads to cancer
2 hours ago
You might not know it, but most of us are infected with the herpesvirus known as Epstein-Barr virus (EBV). For most of us, the virus will lead at worst to a case of infectious mononucleosis, but sometimes, ...
Eat more, weigh less: Worm study provides clues to better fat-loss therapies for humans
2 hours ago
Scientists at The Scripps Research Institute (TSRI) have discovered key details of a brain-to-body signaling circuit that enables roundworms to lose weight independently of food intake. The weight-loss circuit is activated ...
Researchers identify liver cancer progenitor cells before tumors become visible
2 hours ago
For the first time, researchers at the University of California, San Diego School of Medicine have isolated and characterized the progenitor cells that eventually give rise to malignant hepatocellular carcinoma ...
Malaria, toxoplasmosis: Toward new lines of research?
3 hours ago
A study realized by teams from the Institut Pasteur, the Institut Cochin and the Wellcome Trust Centre for Molecular Parasitology of the University of Glasgow, could redefine part of the present lines of research toward a ...
User comments
© Medical Xpress 2011-2013, Phys.org network
A research team from Dana-Farber/Boston Children's Cancer and Blood Disorders Center and other institutions has discovered a new genetic target for potential therapy of sickle cell disease (SCD). The target, called an enhancer, controls a molecular switch in red blood cells called BCL11A that, in turn, regulates hemoglobin production.
The researchers—led by Daniel Bauer, MD, PhD, and Stuart Orkin, MD, of Dana-Farber/Boston Children's—reported their findings today in Science.
Prior work by Orkin and others has shown that when flipped off, BCL11A causes red blood cells to produce fetal hemoglobin that, in SCD patients, is unaffected by the sickle cell mutation and counteracts the deleterious effects of sickle hemoglobin. BCL11A is thus an attractive target for treating SCD.
The disease affects roughly 90,000 to 100,000 people in the United States and millions worldwide.
However, BCL11A plays important roles in other cell types, including the immune system's antibody-producing B cells, which raises concerns that targeting it directly in sickle cell patients could have unwanted consequences.
The discovery of this enhancer—which regulates BCL11A only in red blood cells—opens the door to targeting BCL11A in a more precise manner. Approaches that disable the enhancer would have the same end result of turning on fetal hemoglobin in red blood cells due to loss of BCL11A, but without off-target effects in other cell types.
The findings were spurred by the observation that some patients with SCD spontaneously produce higher levels of fetal hemoglobin and enjoy an improved prognosis. The researchers found that these individuals possess naturally occurring beneficial mutations that function to weaken the enhancer, turning BCL11A's activity down and allowing red blood cells to manufacture some fetal hemoglobin.
"This finding gives us a very specific target for sickle cell disease therapies," said Orkin, a leader of Dana-Farber/Boston Children's who serves as chairman of pediatric oncology at Dana-Farber Cancer Institute and associate chief of hematology/oncology at Boston Children's Hospital. "Coupled with recent advances in technologies for gene engineering in intact cells, it could lead to powerful ways of manipulating hemoglobin production and new treatment options for hemoglobin diseases."
"This is a very exciting study," said Feng Zhang, PhD, a molecular biologist and specialist in genome engineering at the McGovern Institute for Brain Research at the Massachusetts Institute of Technology (MIT) and the Broad Institute of MIT and Harvard, who was not involved in the study. "The findings suggest a potential new approach to treating sickle cell disease and related diseases, one that relies on nucleases to remove this regulatory region, rather than adding an exogenous gene as in classic gene therapy."
Explore further: Researchers highlight potential gene therapy approach to sickle cell disease
More information: "An Erythroid Enhancer of BCL11A Subject to Genetic Variation Determines Fetal Hemoglobin Level" Science, 2013.
Medical Xpress on facebook
Related Stories
Researchers highlight potential gene therapy approach to sickle cell disease
Dec 11, 2012
Researchers at Dana-Farber/Children's Hospital Cancer Center (DF/CHCC) have taken the first preliminary steps toward developing a form of gene therapy for sickle cell disease. In an abstract presented on Dec. 10 at the 54th ...
Scientists reverse sickle cell anemia by turning on fetal hemoglobin
Oct 13, 2011
Not long after birth, human babies transition from producing blood containing oxygen-rich fetal hemoglobin to blood bearing the adult hemoglobin protein. For children with sickle cell disease, the transition from the fetal ...
New approach to sickle-cell disease shows promise in mice
Dec 07, 2009
A new genetic approach to treating sickle cell disease is showing promising results in mice, report researchers from Children's Hospital Boston. By inactivating a gene they previously discovered to be important in the laboratory, ...
Researchers find new genetic target for sickle cell disease therapy
Dec 04, 2008
Researchers have identified a gene that directly affects the production of a form of hemoglobin that is instrumental in modifying the severity of the inherited blood disorders sickle cell disease and thalassemia. The discovery ...
Gene variant linked to moderated symptoms of beta-thalassemia
Jan 30, 2008
Beta-thalassemia is a serious, potentially life-threatening disease that affects red blood cells, cells that carry oxygen via hemoglobin throughout the body. As part of the SardiNIA Study of Aging, supported by the National ...
Recommended for you
Molecule produced during exercise boosts brain health
1 hour ago
Research has shown that exercise is good for the brain. Now investigators have identified a molecule called irisin that is produced in the brain during endurance exercise and has neuroprotective effects. Researchers were ...
Circadian rhythms in skin stem cells protect us against UV rays
2 hours ago
Human skin must cope with UV radiation from the sun and other harmful environmental factors that fluctuate in a circadian manner. A study published by Cell Press on October 10th in the journal Cell Stem Cell has revealed that h ...
How a ubiquitous herpesvirus sometimes leads to cancer
2 hours ago
You might not know it, but most of us are infected with the herpesvirus known as Epstein-Barr virus (EBV). For most of us, the virus will lead at worst to a case of infectious mononucleosis, but sometimes, ...
Eat more, weigh less: Worm study provides clues to better fat-loss therapies for humans
2 hours ago
Scientists at The Scripps Research Institute (TSRI) have discovered key details of a brain-to-body signaling circuit that enables roundworms to lose weight independently of food intake. The weight-loss circuit is activated ...
Researchers identify liver cancer progenitor cells before tumors become visible
2 hours ago
For the first time, researchers at the University of California, San Diego School of Medicine have isolated and characterized the progenitor cells that eventually give rise to malignant hepatocellular carcinoma ...
Malaria, toxoplasmosis: Toward new lines of research?
3 hours ago
A study realized by teams from the Institut Pasteur, the Institut Cochin and the Wellcome Trust Centre for Molecular Parasitology of the University of Glasgow, could redefine part of the present lines of research toward a ...
User comments
© Medical Xpress 2011-2013, Phys.org network
0 comments:
Post a Comment